Lipids Guideline


Guiding Principles

CKD is associated with abnormalities of lipid metabolism. CKD patients are typically initiated on a HMG-CoA Reductase Inhibitor (statin) with the intention of lowering their risk of cardiovascular related mortality and morbidity.

Lipid levels are not usually monitored after this initial intervention.

GFR 15 - 5 | Slow Decline/Deteriorating | Last 0-5 years of life

Patients will not likely receive any benefit from remaining on statins in the last few years of life; some research even suggests an improvement in quality of life from stopping statins. In line with a conservative care philosophy of decreasing therapeutic burden, it is recommended that care providers, in discussion with the patient, discontinue statins for CKM patients at this stage.

GFR 5 - 0 | Intensive/Near Death | Last 0-2 months of life

If not discontinued already, statins should now be stopped.

Additional Resources:

Warning, this site doesn't support the web browser version you are using.

Thus, certain functions may be missing or appear to be broken. Please considering updating your browser to improve your web experience.